Latent Tb: Getting Life Insurance?

Tuberculosis (TB) is a serious health condition that usually affects the lungs. When someone is sick with TB, it is called active TB or TB disease. Active TB can spread from person to person through the air, for example, when an infected person sneezes or coughs. However, it is not possible to get TB from someone with latent TB, also known as latent TB infection (LTBI). LTBI is when a person is infected with Mycobacterium tuberculosis but does not have active TB. While active TB is contagious, LTBI is not.

The identification and treatment of people with LTBI is crucial for controlling the spread of TB. Various treatment regimens are available for LTBI, typically lasting several months. A course of antibiotic medicine, such as Rifampicin and Isoniazid, is often used to treat LTBI.

The question of whether someone with LTBI can get life insurance is complex and depends on various factors, including the individual's location, insurance providers, and personal circumstances. While I cannot provide a definitive answer, I can offer some insights into the broader context of LTBI and insurance coverage.

In the United States, for example, more than 70% of TB cases occur in non-US-born individuals, and this population experiences a lower rate of decline in TB incidence compared to US-born individuals. Strategies to expand LTBI-focused TB prevention may depend on LTBI-positive individuals' access to healthcare and their ability to pay for it.

In general, individuals with LTBI may face challenges in obtaining life insurance due to the potential risk of developing active TB. Insurance providers may consider LTBI as a pre-existing condition that could increase future healthcare costs. However, the impact of LTBI on insurance eligibility and premiums can vary depending on the insurance provider's policies and the individual's overall health status.

It is essential to note that the availability and accessibility of life insurance for individuals with LTBI may differ across countries and regions. The stigma associated with TB, as well as varying healthcare systems and insurance markets, can influence the options available to individuals with LTBI.

To get a clear understanding of their options, individuals with LTBI should consult with insurance providers in their respective locations and seek advice from healthcare professionals and insurance experts.

What is latent tuberculosis?

Latent tuberculosis (LTB), also known as latent tuberculosis infection (LTBI), is when a person is infected with Mycobacterium tuberculosis but does not exhibit symptoms of active tuberculosis (TB). While active TB is contagious, latent TB is not, and it is therefore not possible to get TB from someone with latent TB.

People with latent TB do not feel sick and do not exhibit any symptoms. They also cannot spread TB. However, if they do not receive treatment, they may develop active TB in the future, spread the disease to others, and become unwell.

LTBI is typically diagnosed through a tuberculin skin test (TST) on the forearm, a TB blood test, or a chest radiograph (x-ray) if either of the first two tests is positive.

LTBI is usually treated with the antibiotic isoniazid (INH) once daily for nine months. Another option for children aged two and above is once-weekly therapy with isoniazid and rifapentine for a total of 12 weeks.

LTBI is widespread, with approximately one-third of the world's population latently infected with M. tuberculosis. However, the prevalence varies across regions, with around 80% of the population in many Asian and African countries testing positive on tuberculin tests, compared to only 5-10% in the US.

What are the treatment options?

Treatment Options for Latent TB

There are several treatment options for latent tuberculosis (TB), which is when a person is infected with Mycobacterium tuberculosis but does not exhibit symptoms of active TB. It is important to treat latent TB to prevent it from progressing into active TB, which is contagious and can be spread to others.

The specific treatment regimen chosen will depend on various factors, such as the patient's medical history, coexisting medical conditions, and potential drug interactions. It is important to consult a medical professional for personalized advice. That being said, here are some of the most common treatment options for latent TB:

• Isoniazid (INH): This is the most commonly used treatment for latent TB. In the US, the standard treatment regimen is isoniazid for nine months. However, this regimen is not widely used outside of the US. Isoniazid can also be combined with other drugs, such as rifapentine or rifampin, to form a short-course treatment regimen.
• Rifapentine (RPT): This medication is often used in combination with isoniazid to treat latent TB. The patient typically meets with their doctor or nurse once a week for 12 weeks to receive and take the medication.
• Rifampin (RIF): Rifampin is another alternative treatment for latent TB. It can be taken on its own for four months or in combination with isoniazid for three months.
• Short-course treatment regimens: The Centers for Disease Control and Prevention (CDC) and the National Tuberculosis Controllers Association (NTCA) recommend short-course, rifamycin-based treatment regimens over longer isoniazid monotherapy. Examples include three months of once-weekly isoniazid plus rifapentine (3HP) or four months of daily rifampin (4R). These short-course regimens are effective, safe, and have higher completion rates compared to longer isoniazid monotherapy. They also generally have a lower risk of hepatotoxicity.
• Long-course treatment regimens: If short-course treatment regimens are not feasible or available, longer isoniazid monotherapy regimens, such as six or nine months of isoniazid (6H or 9H), are effective alternative treatment options. However, these longer regimens have a higher toxicity risk and lower treatment completion rates compared to short-course regimens.
• Other treatment regimens: Other treatment regimens for latent TB include three months of daily isoniazid plus rifampin (3HR) and two months of rifampin and pyrazinamide (2RZ). However, the 2RZ regimen is no longer recommended due to an increased risk of drug-induced hepatitis and death.

It is important to note that all treatment regimens must be modified if the patient has been in contact with an individual with drug-resistant TB. Clinicians should carefully select the appropriate treatment regimen based on drug susceptibility results, coexisting medical conditions, and potential drug interactions. Consultation with a TB expert is advised if the known source of TB infection is drug-resistant.

What are the side effects of treatment?

The side effects of treatment for latent tuberculosis (TB) can vary depending on the specific medication and the individual patient. Some people may experience no side effects at all, while others may experience mild or more serious side effects. It's important to remember that the treatment for latent TB is crucial to preventing the development of active TB, which can be contagious and spread to others. Here are some of the possible side effects of latent TB treatment:

• Rifinah (Rifampicin and Isoniazid combination): This medication can cause orange staining of tears, saliva, urine, and other bodily fluids. It is not harmful, but it may stain contact lenses. It can also lead to menstrual disturbances, reduced effectiveness of hormonal contraceptives, tingling or numbness, rashes, itchiness, sickness, and diarrhoea.
• Isoniazid: This drug may cause hepatitis, which can result in fatigue, decreased appetite, abdominal discomfort, nausea, and jaundice. It can also lead to peripheral neuropathy, which includes symptoms such as "pins and needles" and subjective sensory loss.
• Rifampicin: This medication can cause gastrointestinal symptoms such as abdominal pain and nausea, dermatological reactions, hypersensitivity reactions, hematological side effects, and hepatotoxicity. It can also turn urine and other body fluids orange, which can stain soft contact lenses and dentures. Rifampicin interacts with several drugs, including antiretrovirals, anticonvulsants, warfarin, azole antifungals, methadone, and immunosuppressants.
• Rifapentine: As a rifamycin derivative, Rifapentine shares similar drug interactions and toxicity profiles with Rifampicin.

It's important to note that the side effects of these medications are typically mild and transient. However, if you experience any concerning symptoms or side effects, it's crucial to consult your doctor or nurse immediately. They will be able to provide support and guidance throughout your treatment journey.

Why is treatment important if I feel healthy?

While people with latent tuberculosis (LTB) do not feel sick and are not contagious, they are still infected with Mycobacterium tuberculosis. This means that there is a risk of the bacteria becoming active and leading to active tuberculosis (TB), which is contagious and can be spread to others. Treatment is important as it can prevent the latent TB bacteria from becoming active and causing illness.

About 1 in 10 people with latent TB will develop active TB, and there is no way to know if you will be one of them. It is possible to become ill with active TB many years after a person breathes in TB bacteria. Treatment is the only way to remove the TB bacteria from your body.

Latent TB treatment is often shorter than treatment for active TB and involves less medication. These are good reasons to treat latent TB while you are healthy and before the bacteria have a chance to become active.

The usual treatment for latent TB is taking an antibiotic called Isoniazid (INH) once daily for nine months. Another option for children 2 years old and older is once-weekly therapy with Isoniazid and Rifapentine for a total of 12 weeks.

It is important to remember that even after completing the full course of medication, there is no guarantee that all the TB bacteria have been killed. Therefore, it is essential to remain alert to the symptoms of active TB for the remainder of your life.

How do I take the medication?

It is important that you take your medicine regularly and complete the full course, to ensure all TB bacteria are removed from your body.

Try to take your TB medicine at least one hour before you eat food or two hours afterward. You can eat anything you like, but you should avoid drinking alcohol. It is best to take your medications without food, but if your stomach is upset, it is okay to take them with a small amount of food.

Depending on your specific circumstances, your doctor may recommend one of several treatment regimens for latent TB. These regimens may include the following medications, used on their own or in combination:

• Isoniazid (INH)
• Rifapentine (RPT)
• Rifampin (RIF)

The CDC and the National Tuberculosis Controllers Association (NTCA) recommend short-course, rifamycin-based, 3- or 4-month latent TB infection treatment regimens over 6- or 9-month isoniazid monotherapy. Short-course regimens include:

• Three months of once-weekly isoniazid plus rifapentine (3HP)
• Four months of daily rifampin (4R)
• Three months of daily isoniazid plus rifampin (3HR)

Short-course treatment regimens are effective, safe, and have higher completion rates than longer 6- to 9-month isoniazid monotherapy. Shorter, rifamycin-based treatment regimens generally have a lower risk of hepatotoxicity than longer alternatives.

If short-course treatment regimens are not feasible or available, 6H and 9H are alternative, effective latent TB infection treatment regimens. While these longer regimens are effective, they have a higher toxicity risk and lower treatment completion rates than most short-term treatment regimens.

The standard treatment in the US is nine months of isoniazid, but this regimen is not widely used outside of the country. In the UK, the recommended regimen is six months of isoniazid.

Regardless of the treatment regimen you are prescribed, it is important to remember to take your TB medicine as your doctor or nurse instructs. If you miss too many days, the medicine might not work.

Frequently asked questions